Industry: Healthcare
Published Date: August-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 190
Report ID: PMRREP20122
The immune checkpoint inhibitors market is estimated to reach a valuation of US$107 billion by the year 2034, at a CAGR of 15%, during the forecast period 2024 to 2034.
Key Highlights of the Market
|
Attributes |
Key Insights |
|
Market Size (2024) |
US$26 bn |
|
Market Size (2034) |
US$107 bn |
|
Forecast Growth Rate (CAGR 2024 to 2034) |
15% |
|
Historical Growth Rate (CAGR 2019 to 2023) |
9.5% |
North America’s Dominance to Prevail Through the End of 2034
|
Region |
Market Value Share 2023 |
|
North America |
65% |
In 2023, North America accounted for the majority of revenue in the immune checkpoint inhibitors market, with a share of 65%, owing to the high occurrence of neoplasms in the region.
According to the Leukemia & Lymphoma Society (LLS), roughly one individual in the United States is diagnosed with lymphoma, myeloma, and leukemia every three minutes. Furthermore, as per the CDC, there were around 1,603,844 newly reported cancer cases in the United States in 2020.
Moreover, the market growth is being enhanced by the establishment of additional immunotherapy institutes in the region.
In March 2022, The University of Texas MD Anderson Cancer Center established the James P. Allison Institute with the aim of creating innovative immunotherapy therapies, including immune checkpoint inhibitors, within the United States.
Furthermore, the market expansion is being propelled by the increased FDA approval of novel immune checkpoint inhibitors in the region. In February 2021, the U.S. FDA granted permission to Regeneron Pharmaceuticals Inc. for the use of Libtayo (cemiplimab-rwlc) in the treatment of non-small cell lung cancer.
PD-1 Accounts for 70% Market Share
|
Market Segment by Type |
Market Value Share 2023 |
|
PD-1 |
70% |
Based on type, the global immune checkpoint inhibitors market is further classified into PD-1, PD-L1, and CTLA-4, where the PD-1 segment dominates the market. PD-1 inhibitors have shown effectiveness in a wide range of tumors, such as melanoma, lung and bladder cancer, and others.
The widespread adoption of many cancer types is driven by favorable clinical outcomes and persistent responses. In addition, PD-1 inhibitors are frequently utilized in conjunction with various cancer treatments, including chemotherapy, targeted medicines, and CTLA-4 inhibitors.
Further, the PD-L1 segment is projected to have the highest compound annual growth rate (CAGR) over the forecast period. PD-L1 inhibitors, including Atezolizumab (Tecentriq), Avelumab (Bavencio), and Durvalumab (Imfinzi), are becoming increasingly popular because of their strong effectiveness.
These medications can be utilized either in combination or separately for a range of purposes, such as treating non-small cell lung cancer and metastatic Merkel-cell carcinoma.
Lung Cancer Remains the Primary Area of Application
|
Market Segment by Application |
Market Value Share 2023 |
|
Lung Cancer |
25% |
Based on application, the global immune checkpoint inhibitors market is further divided into lung cancer, breast cancer and melanoma, where the lung cancer segment dominates the market share.
Lung cancer is the primary cause of mortality worldwide, as stated by the World Health Organization (WHO). According to GLOBOCAN, the projected number of lung cancer cases is expected to rise from 2.48 million in 2022 to 3.05 million by 2030.
The increasing occurrence and death rate caused by lung cancer is a significant element that contributes to the expansion of this particular category. Furthermore, firms in the market are consistently engaged in the creation and introduction of innovative immune checkpoint inhibitors for the treatment of lung cancer patients.
The medicine is recommended for individuals diagnosed with stage IB, II, or IIIA non-small cell lung cancer. Therefore, the increasing use of immune checkpoint inhibitors in treatment is fuelling the expansion of this category.
The rising global incidence of different types of cancer greatly drives the market for immune checkpoint inhibitors (ICIs). There is an anticipated rise in the market for immune checkpoint inhibitors (ICIs) due to their promising efficacy in the treatment of several forms of cancer.
The immune checkpoint inhibitors (ICIs) market is propelled by increasing research and progress in cancer immunotherapy, namely in the field of ICIs.
The immune checkpoint inhibitor market is expanding as a result of continuous endeavours to enhance understanding of the immune system's involvement in cancer and the development of inventive immunotherapeutic approaches.
The growth of the immune checkpoint inhibitor market is driven by the progress in healthcare infrastructure in emerging markets and the accessibility of state-of-the-art cancer therapies. The utilization of immune checkpoint inhibitors is expected to increase as healthcare systems advance and become more refined.
The market expansion for immune checkpoint inhibitors in different cancer types and new indications is made possible by obtaining regulatory approvals. The market potential for ICIs increases as the number of permitted uses expands.
The global immune checkpoint inhibitors market has experienced significant growth from 2019 to 2023. This period was marked by substantial advancements in immunotherapy, a surge in cancer prevalence, and increased investment in biotechnology and pharmaceutical research and development.
In 2019, the immune checkpoint inhibitors market witnessed robust growth due to the rising incidence of various cancers and the increasing adoption of immunotherapy as a treatment modality.
The approval of new immune checkpoint inhibitors by regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), further fuelled market expansion.
Key products like pembrolizumab (Keytruda) and nivolumab (Opdivo) dominated the market, driven by their proven efficacy in treating multiple cancer types.
In 2023, the global immune checkpoint inhibitors market reached new heights, driven by continued innovation and broader acceptance of immunotherapy. The market saw the introduction of novel inhibitors with improved efficacy and safety profiles.
Efforts to expand access to these therapies in emerging markets also contributed to the overall growth. The integration of artificial intelligence and machine learning in drug development and patient care optimized treatment regimens, enhancing the effectiveness of immune checkpoint inhibitors.
By the end of 2023, the market had established itself as a crucial component of modern oncology treatment, with a promising outlook for future advancements.
Rising Incidence of Cancer
One of the primary drivers of the global immune checkpoint inhibitors market is the increasing incidence of cancer worldwide. Cancer remains one of the leading causes of morbidity and mortality globally, with millions of new cases diagnosed each year.
As the global population ages and lifestyles change, the prevalence of cancer is expected to rise, creating a larger patient pool requiring innovative and effective treatment options. Immune checkpoint inhibitors, which have shown remarkable efficacy in treating various cancers, are in high demand, driving market growth.
Advancements in Immunotherapy
Technological advancements and scientific breakthroughs in immunotherapy have significantly propelled the immune checkpoint inhibitors market. Over the past decade, research has unveiled the critical role of the immune system in combating cancer, leading to the development of therapies that enhance the body's immune response against tumour cells.
Immune checkpoint inhibitors, which target specific proteins that regulate immune checkpoints, have emerged as a cornerstone of modern oncology. Their ability to provide durable responses and improve survival rates in patients with advanced cancers has positioned them as a preferred treatment option, stimulating market expansion.
Increasing Approvals and Indications
Regulatory approvals of new immune checkpoint inhibitors and the expansion of indications for existing ones have been pivotal in driving market growth. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved several immune checkpoint inhibitors for various cancer types, including melanoma, non-small cell lung cancer, renal cell carcinoma, and more.
These approvals not only enhance the therapeutic arsenal available to oncologists but also encourage pharmaceutical companies to invest in the development of new inhibitors and combination therapies, further fuelling market growth.
High Cost of Treatment
One of the most significant restraints affecting the growth of the global immune checkpoint inhibitors market is the high cost associated with these treatments. Immune checkpoint inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), are often priced at a premium due to the substantial investment in research and development, complex manufacturing processes, and the high cost of clinical trials.
The cost of a single course of treatment can reach tens of thousands of dollars, making it prohibitively expensive for many patients and healthcare systems, especially in low and middle-income countries.
Impact on Patients and Healthcare Systems
The high cost of immune checkpoint inhibitors limits patient access, particularly for those without comprehensive health insurance or in countries where healthcare coverage is inadequate.
Patients may face significant out-of-pocket expenses, leading to financial hardship or inability to afford treatment. This financial barrier not only affects individual patients but also places a heavy burden on healthcare systems and insurance providers.
As a result, the adoption and utilization of these therapies can be restricted, impacting the overall growth of the market.
Introduction of Novel Immune Checkpoint Inhibitors
The success rate of cancer treatment has increased due to advancements in therapeutic outcomes, leading to more sophisticated treatment methods. This achievement has been made possible as a result of improved comprehension of the pathophysiology of the disease, the activity of tumour cells, and the development of efficient strategies to address them.
Immune checkpoint inhibitors demonstrate a lower incidence of side effects in comparison to conventional cancer treatments like chemotherapy, radiation therapy, and other modalities.
Manufacturers are now developing immune checkpoint inhibitors that are specifically designed to target and inhibit specific molecules. In addition, medicines targeting specific immune regulatory checkpoints, such as programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1), including Nivolumab, Atezolimumab, and Pembrolizumab, are being utilized for the treatment of non-small cell lung cancer.
The global immune checkpoint inhibitors market is characterized by intense competition among a mix of established pharmaceutical giants and emerging biotechnology companies.
Key players in the market include Merck & Co., Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer, which dominate due to their extensive product portfolios, robust R&D capabilities, and strong global presence.
The competitive landscape of the global immune checkpoint inhibitors market is dynamic and multifaceted, driven by innovation, strategic partnerships, and a relentless pursuit of market leadership.
The interplay between established pharmaceutical leaders and nimble biotechnology firms ensures ongoing advancements and robust competition in this rapidly evolving market.
Recent Industry Developments
In Sep 2023, the U.S. FDA accepted Merck & Co.s supplemental new drug application for WELIREG (belzutifan), granting it priority review status. This medication is prescribed for patients who have already had treatment and are experiencing renal cell carcinoma.
In Oct 2023, Bristol Myers Squibb obtained approval from the U.S. FDA for the use of Opdivo (nivolumab) in treating removed stage IIB or Stage IIC melanoma in patients aged 12 years and above, both adults and children.
In Jan 2023, Merck & Co initiated a clinical trial collaboration with Teon Therapeutics to assess the efficacy of TT-816 in conjunction with KEYTRUDA (pembrolizumab). This medication is specifically prescribed for people who have advanced solid tumours.
|
Attributes |
Details |
|
Forecast Period |
2023 – 2034 |
|
Historical Data Available for |
2019 – 2023 |
|
Market Analysis |
US$ Billion for Value |
|
Key Regions Covered |
|
|
Key Companies Profiled |
|
|
Pricing |
Available upon request |
By Type
By Application
By Distribution Channel
By Region
To know more about delivery timeline for this report Contact Sales
The global immune checkpoint inhibitors market is estimated to exhibit a CAGR of 15% during the forecast period.
North America is the leading region in the market.
The market is segmented based on type, application and distribution channel.
Sanofi, F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Eli Lilly and Company, are some of the major key companies in the market.
PD-1 type dominates the market share.
